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To determine whether enhancer elements in addition to the highly conserved octamer (OCTA)-nucleotide
motif are important for lymphoid-specific expression of the immunoglobulin heavy-chain (IgH) gene, we have
investigated the effect of mutating the binding site for a putative additional lymphoid-specific transcription
factor, designated NF-,uB, in the murine IgH enhancer. We demonstrate that the NF-,uB-binding site plays a
critical role in the IgH enhancer, because mutation of the ,uB DNA motif decreased transcriptional activity of
the IgH enhancer in cells of the B-cell lineage but not in nonlymphoid cells. This effect was comparable to or
even stronger than the effect of a mutation in the OCTA site. Moreover, combined mutation of both ,B and
OCTA sites further reduced enhancer activity in lymphoid cells. Interestingly, alteration of either the ,uB or
E3 site in a 70-base-pair fragment of the IgH enhancer that lacks the binding site for OCTA abolished enhancer
activity in lymphoid cells completely. Nevertheless, a multimer of the ,uB motif alone showed no enhancer
activity. DNase footprinting analysis corroborated the functional data showing that a lymphoid-specific protein
binds to the ,uB DNA motif. Our results suggest that the 1,B element is a new crucial element important for
lymphoid-specific expression of the IgH gene but that interaction with another enhancer element is essential for
its activity.
The 700-base-pair (bp)-long immunoglobulin heavy-chain
(IgH) enhancer shows a complex modular structure of a
variety of overlapping positive-acting enhancer elements and
negative-acting elements (for a review, see reference 35).
The majority of these elements appear to bind ubiquitous
transcription factors that are present in both lymphoid and
nonlymphoid cells (2, 8, 16, 28, 31, 32, 34, 35). The E boxes
El, E2, E3, and E4 represent one group of such enhancer
elements (6, 8, 16, 23). Mutational studies have suggested
that the E-box elements contribute to the transcriptional
regulation of the IgH gene but do not determine lymphoid
specificity (13, 16, 27, 42). An additional enhancer element,
E, has been identified by binding of a protein designated
R-EBP (42). Deletion analysis has provided evidence for
functional importance of this element (42). Negative ele-
ments present in the enhancer appear to be active only in
nonlymphoid cells and thus might contribute to lymphoid-
specific expression of the IgH enhancer (30, 44).
Only one enhancer element thus far characterized, a
highly conserved octamer (OCTA)-nucleotide motif, ATTT
GCAT, has been shown to confer some lymphoid specificity
to the IgH gene (for a review, see reference 35). OCTA binds
a variety of ubiquitous and cell-restricted factors (17, 33, 39).
The Oct-1 transcription factor is ubiquitously expressed in
all cell types (15, 39, 41), whereas Oct-2 expression is
restricted to B cells, some T cells, and some glial cells (14,
15, 38, 39). The OCTA-nucleotide sequence is present in
both the IgH promoter and enhancer (3, 9, 19, 25, 36) and has
been found in a variety of other genes (4, 5, 18, 20, 26, 37).
Nevertheless, mutation of the OCTA sequence in the con-
text of the whole IgH enhancer has only very little effect on
its activity in lymphoid cells (16, 27), suggesting the presence
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of additional lymphoid-specific enhancer elements. Indeed, a
460-bp fragment of the IgH enhancer that lacks the OCTA
sequence retains substantial lymphoid-specific enhancer ac-
tivity (16; this paper).
Araki et al. (1) have recently shown that introduction of
nuclear extracts from myeloma cells into murine L cells
containing the human IgH gene leads to specific expression
of the IgH gene. However, depletion of OCTA-nucleotide-
binding factors from myeloma nuclear extracts did not
diminish induction of IgH gene expression in L cells (1).
They identified a new nuclear factor that showed character-
istics of a second lymphoid-specific transcription factor.
This factor has been purified from a murine myeloma and
binds to the sequence 5'-TATTT'TAGGAAGCAAA-3' in the
human IgH enhancer just downstream of the E3 motif (1).
The murine IgH enhancer contains a similar but not identical
sequence at the same location (Fig. 1). The purified factor
has been shown to induce expression in the human IgH gene
in murine L cells and thus may play a critical role in IgH
gene expression (1).
To determine the functional role of this new factor,
designated NF-,uB in this study, we have introduced muta-
tions into the homologous NF-,uB- and OCTA-binding sites
of the murine IgH enhancer. We tested whether the murine
IgH enhancer ,uB element is functionally comparable to the
human IgH enhancer element and whether the ,uB motif
could be responsible for the lymphoid-specific expression of
an OCTA-deleted IgH enhancer. We have found that muta-
tion of [LB reduces activity of the murine IgH enhancer in
pre-B, mature B, and plasma cells but not in NIH 3T3
fibroblasts. We have narrowed down the lymphoid-specific
element to a 70-bp fragment that contains ,uB and E3 but not
OCTA. In contrast to other enhancer elements, no intrinsic
enhancer activity was detected with the puB motif by itself,
suggesting a necessity for interaction with another enhancer
element. Our results suggest that ,uB together with OCTA
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FIG. 1. Structures of IgH enhancer constructs used for transfec-
tions. (A) Schematic diagram of mutations introduced into the
murine IgH enhancer. Filled symbols represent the various tran-
scription factor-binding sites. The circle indicates the OCTA motif;
boxes show the different E-box sites; the diamond indicates the [LB
DNA motif. The wild-type sequences of E3, ,uB, and OCTA are
indicated by the expansions above and below the diagram. Arrows
point to the nucleotides introduced by mutations into the wild-type
sequence. Open boxes represent exons for the constant and variable
regions; the thin line indicates the intron. The enhancer fragment
referred to as ,u700 extends between the XbaI and EcoRI sites. p.300
extends between the PvuII and EcoRI sites. The segment referred to
as pu460 extends between the XbaI and AluI sites, and fragment p70
extends between the PvuII and AluI sites. (B) The insertion site
(Sall) for enhancer fragments into the c-fos promoter A56/CAT
fusion plasmid 56 bp upstream of the transcription start site. The B
orientation is the reverse orientation of the enhancer fragments
shown in panel A.
may determine most of the lymphoid-specific expression of
the IgH gene and demonstrate that the ,uB DNA motif binds
a lymphoid-specific factor or factors.
MATERIALS AND METHODS
Cell culture. S194 (murine myeloma), NIH 3T3 (murine
fibroblast), HeLa (human cervical carcinoma), U-C12:6 (hu-
man glioma), and EJ (human bladder carcinoma) cells were
grown in Dulbecco modified Eagle medium containing 10%
fetal calf serum. PD31 (murine Abelson murine leukemia
virus-transformed pre-B cell line) and BJAB (human B-cell
lymphoma) cells were maintained in RPMI 1640 supple-
mented with 10% fetal calf serum and 50 p.M 2-mercaptoeth-
anol. HAFTL (murine Harvey v-ras-transformed early pre-
B-cell line) cells were grown in RPMI 1640 medium
containing 15% fetal calf serum and 50 p.M 2-mercaptoeth-
anol. 32D (murine early myeloid cell line) cells were grown
in RPMI 1640 supplemented with 5% fetal calf serum and
10% conditioned medium from WEHI 3 cells.
Nuclear extracts. Nuclear extracts were prepared accord-
ing to the method of Dignam et al. (7). Nuclear extract from
32D cells was kindly provided by Stephen Smale (Whitehead
Institute). Heparin-agarose fractions of nuclear extracts
from HeLa and BJAB cells were kindly provided by Mark
Kamps (Whitehead Institute).
Enhancer/chloramphenicol acetyltransferase (CAT) plas-
mid construction. The XhoI-linkered 700-bp IgH enhancer
and fragments thereof were inserted into the Sall site in the
A-56-c-fos-CAT plasmid described by Gilman et al. (10) and
Lenardo et al. (16) in the B orientation (Fig. 1B).
A synthetic 34-bp ,uB oligonucleotide
5'-TCGAGCAAGGCTATTTGGGGAAGGGAAAATAAAG-3'
3'-CGTTCCGATAAACCCCTTCCCTTTTATTTCAGCT-5'
containing Sall and XhoI ends was inserted as a monomer,
dimer, and tetramer into the Sall site in the A56-c-fos-CAT
plasmid (10, 16).
Site-directed mutagenesis. Plasmids containing mutations
in either OCTA or E3 were derived from plasmids described
by Lenardo et al. (16). Specific site-directed mutagenesis of
three nucleotides in the ,uB DNA motif of the murine IgH
enhancer between positions 414 and 427 was introduced by
the gapped/heteroduplex method (40), using an oligonucleo-
tide 5'-GTGGCAAGGCTATTTGTCAAAGGGAAAATAA-
3' (Fig. 1A).
DNA transfection assays. Transfections of cells were car-
ried out with 10 ,ug of IgH enhancer/A56 plasmid, using the
DEAE-dextran method (16, 29). NIH 3T3 cells were trans-
fected by the calcium phosphate coprecipitation method (16,
29). The cells were harvested 48 h after transfection, and 30
to 100 p.g of heat-inactivated (16) cell extract was assayed for
CAT activity as described previously (11) in a 1-h incubation
at 37°C. Transfections for every construct were performed
independently in duplicate and repeated two to four times.
Samples were analyzed by thin-layer chromatography (11).
The percentage of acetylated chloramphenicol was deter-
mined by cutting out nonacetylated and acetylated forms of
chloramphenicol and measuring the amount of radioactivity
by liquid scintillation counting.
DNase I footprinting analysis. p.460/A56 and ,u460 p.B-/
A56 (Fig. 1 and 2) were linearized with HindlIl, dephospho-
rylated, and end labeled with [-y-32P]ATP and T4 polynucle-
otide kinase at the 5' end of the noncoding strand. After
digestion with SalI, end-labeled ,u460 and ,u460 uB-
HindIII-SalI fragments were gel purified. DNase I footprint-
ing was performed as described by Jones et al. (12), using 0.3
to 0.8 ng of end-labeled IgH enhancer fragments (5,000 cpm),
20 ,ug of total nuclear extract, 3 ,ug of heparin-agarose-
purified nuclear extract, or no protein, 1 ,ug of poly(dI-dC)
for total nuclear extract and 0.2 ,ug for heparin-agarose
fractions, and 2% polyvinyl alcohol in 50 ,ul. A ladder of
G+A Maxam-Gilbert (21) sequence reaction of the labeled
IgH enhancer fragments was run as a marker.
RESULTS
Lymphoid-specific transcription of the IgH enhancer is for
the most part dependent on two enhancer elements, OCTA
and ,uB. The ,uB site (Fig. 1A) was identified as a putative
lymphoid-specific enhancer element (1) along with the
OCTA motif (16). To study these enhancer elements, we
introduced mutations in the p,B, OCTA and E3 sites by using
synthetic oligonucleotides (Fig. 1A). Wild-type and mutant
IgH enhancers as well as fragments thereof (Fig. 2) were
cloned into the Sall site just upstream of the truncated c-fos
promoter of the A56 plasmid (10, 16) in the B orientation
(Fig. 1B). We measured enhancer activity as the ability of
the different enhancer constructs to induce transcription of
the CAT gene after transient expression in a variety of cell
types. The full-length 700-bp IgH enhancer (,u700 WT)
stimulated transcription 50-fold in S194 myeloma cells and
20-fold in PD31 pre-B lymphoid cells (Fig. 2, line 1) relative
to the level of the control plasmid (Fig. 2, line 14). The
transcriptional activities of mutant enhancers were com-
pared with the level of either the full-length or partial
fragments of the wild-type 700-bp IgH enhancer (,u700 WT)
MOL. CELL. BIOL.
LYMPHOID-SPECIFIC ENHANCER ELEMENT IN IgH GENE
0 400 200bAP 300 400 500 600 7001
1 a 700 WT -
2 a 700 0- -
3 #700X#B-
4 , 7000,aB-
5 o300wT
6. ,3000-
7 #300#6B
8 p300 0-#B-
9 &460OrT-
10. # 4608-
If. # 70WT
/2 & 70E3-
13. # 70,8-
4. ENH/-
El E2 E3 E4 OCTA
') ) (riLB ") rrH-B[
-u.-
ur.o.-Do~
JIG* Deo
-4-o]1j LIED pc
JU*-
% Relative Cat Activity
S494, PD3I
100 100
58 89
45 44
45 25
841 318
545 139
396 30
145 14
13.5 n.d.
2.0 n.d.
10.5 n.d.
1.9 nd.
1.8 n.d.
2.0 5.0
FIG. 2. Relative activities of IgH enhancer fragments and mutations in S194 myeloma and PD31 pre-B cells. Symbols indicate the positions
of the different enhancer elements, analogous to those in Fig. 1A. Empty symbols represent wild-type configurations; solid boxes indicate
mutated sites as depicted in Fig. 1A. Deletions are given by the loss of part of the thin line. Half of a box indicates deletion starting in the
middle of the E2 site. The CAT activity of each construct transfected into either S194 or PD31 cells is compared with that of the wild-type
,u700 IgH enhancer/CAT construct in line 1. CAT values are averages derived from one representative experiment of two independent
transfections. Repeated experiments gave similar results, with deviations of less than 20% compared with the values given. ENH- (line 14)
indicates the enhancerless A56 background plasmid.
(Fig. 2 to 4). The 3' 300-bp part of the IgH enhancer (,u300
WT), which lacks El and E2, expressed 8.4- and 3.2-
times-higher CAT activity than did p.700 WT in S194 and
PD31 cells, respectively (Fig. 2, line 5). However, in the A
orientation (16), ,u700 expressed much higher activity than
did ,u300 (data not shown).
Mutation in the OCTA motif within ,u700 (p.700 O-)
reduced CAT activity in S194 myeloma cells by only about
40% (Fig. 2, line 2; Fig. 3A) but had a very small effect in the
pre-B-cell line PD31 (Fig. 2, line 2; Fig. 3B), suggesting the
presence of lymphoid-specific enhancer elements in p.700
independent of OCTA (16). We therefore tested the effect of
a mutation in the p.B DNA motif on enhancer activity.
Mutation in the p.B motif within p.700 (p.700 ,uB-) resulted in
a decrease of about 55% in both S194 and PD31 cells (Fig. 2,
line 3; Fig. 3A and B). Interestingly, mutation in the p.B
DNA motif had an even more drastic effect on transcription
of p.700 in a very early pre-B-cell line, HAFTL, in which the
,uB- mutation reduced CAT activity by more than 80% (Fig.
3C). By contrast, the OCTA mutation had only a slight effect
in this cell line (Fig. 3C). These results suggest that the p.B
site encodes an IgH enhancer element that may be more
important for transcriptional activity in cells early in the
B-lymphoid lineage. By contrast, OCTA appears to play a
larger role in the more mature cells. Strikingly, combined
mutation of both the p.B and OCTA motifs (.700 0- ,uB-)
led to severe decreases in CAT activity in all types of B cells
(Fig. 2, line 4; Fig. 3). These effects were more dramatic than
either mutation alone, reflecting a requirement for both p.B
and OCTA. In S194 and PD31 cells, residual enhancer
activities of 15 and 25% of p.700 WT activity, respectively,
were observed even when both p.B and OCTA sites were
mutated. Thus, further enhancer elements present in the IgH
enhancer must be active.
Similar results were obtained when mutating the OCTA or
p.B motif in the context of the p.300 enhancer fragment (Fig.
1, from the PvuII to EcoRI sites), which lacks El, E2, and
other putative upstream elements (Fig. 2, lines 5 to 8; Fig. 3).
As for p.700, mutations in ,uB always had a stronger effect on
transcription than did mutations in OCTA (Fig. 2, lines 5 to
7; Fig. 3). This was particularly evident in PD31 cells, in
which mutation in p.B decreased CAT activity by more than
10-fold, whereas mutation in OCTA led to only a 2-fold
decrease (Fig. 3B). Double mutation in both p.B and OCTA
within p.300, similar to p.700, caused greater decreases in
transcription than either alone in S194, PD31, and HAFTL
cells (Fig. 2, line 8; Fig. 3).
To assess the functional consequence of the removal of
the whole 3' end of the enhancer, containing both E4 and
OCTA, we created p.460 (Fig. 2, lines 9 and 10). This
deletion led to a drastic reduction of transcription to 13.5%
of the level of p.700 WT in S194 cells, suggesting that
important sites other than OCTA are removed by this
deletion (Fig. 2, line 9). Alterations in the p.B motif within
this construct abrogated all enhancer activity in S194 cells
(Fig. 2, lines 9 and 10). Thus, even though p.460 contains
several E-box elements (El, E2, and E3), mutation of p.B
alone drastically reduces the transcriptional activity of p.460.
This context illustrates most vividly the importance of the
p.B site for the IgH enhancer.
,uB needs a second enhancer element for its function.
Because alteration of the p.B site in p.460 suggested that this
site might be the crucial enhancer element in this fragment,
we made further truncations of the IgH enhancer. p.70 WT,
containing only the E3 and p.B motifs as identified enhancer
elements but lacking El, E2, E4, and OCTA, expressed
transcriptional activity similar to that of p.460 in S194 cells
(Fig. 2, lines 9 and 11). Mutation of either the E3 or p.B site
abolished enhancer activity of p.70 in S194 cells (Fig. 2, lines
11 to 14). Because alteration of E3 had the same effect as
VOL. 10, 1990 3157
3158 LIBERMANN ET AL.
A A l700 u300
b 10 700300
io , 700 ..300 -
'880
Q 60-
~40
20 -.
WT 0- ILK 0-B- ENH- WT 0 /B_ 0-B- ENH-
Fe700 au3300
80
60-
40 --
20-
WT 0- LB_ 0 LB_ ENH_ WT 0- LB_ 0~LB_ ENHW
C
:S' uz700 #i3OO
~.ioo
'880
60 .
40
t1J20 ~
ol~~~~'
0 WT 0- LB- 0~LB_ ENH_ WT 0- uB 0-,B- ENH_
FIG. 3. Effects of mutations on IgH enhancer transcription rate. The p.700 and p.300 IgH enhancers with mutations in either OCTA (0-)
or p.B (,uB-) were tested in S194 myeloma (A), PD31 pre-B (B), and HAFTL early pre-B (C) cells. In each experiment, each value is the
average of two representative independent transfections; repeated experiments gave similar results in which the standard deviations were less
than 20% compared with the values given. Absolute percent conversions of chloramphenicol to acetylated forms were as follows: ,u700 WT,
7.6% for S194, 4.4% for PD31, and 1.8% for HAFTL; pu300 WT, 63.8% for S194, 14% for PD31, and 2.4% for HAFTL (the CAT assays with
pu300 were repeated for S194 cells with less cell extract in order to keep a linear range of chloramphenicol substrate conversion, resulting in
conversion of 29.4% for ,u300 WT); and ENH-, 0.15% for S194, 0.22% for PD31, and 0.26% for HAFTL. Activity is given as percent relative
CAT activity of the wild-type IgH enhancer fragment. Hatched columns represent the parental enhancerless plasmid; dotted columns
represent plasmids containing various versions of the enhancer.
mutating ,uB in this fragment, the simplest explanation is that
,uB does not function by itself but requires a second en-
hancer element such as E3. To test this possibility, we
constructed a synthetic 34-bp oligonucleotide containing the
,uB motif and its flanking region but lacking E3. We inserted
one, two, or four copies of this oligonucleotide into the A56
plasmid. In contrast to the p.70 fragment, no enhancer
activity, even with four copies of the ,uB oligonucleotide,
was detected in S194, PD31, or HAFTL cells (data not
shown). Thus, it appears that the ,uB element does not
function independently as an enhancer but needs interaction
with another enhancer element for activity.
,uB and OCTA are not functional in fibroblasts. To test
whether ,uB is functional in nonlymphoid cells, we trans-
fected the various constructs into NIH 3T3 fibroblasts. All
constructs derived from the p.700 enhancer as well as the ,u70
constructs were inactive in NIH 3T3 cells. p.300 WT ex-
pressed low but reproducible enhancer activity (Fig. 4).
Mutation of the OCTA or [LB site or a combination of both
within p.300 resulted in a two- to threefold increase in CAT
activity in NIH 3T3 cells (Fig. 4). We have not further
investigated the apparent inhibitory effects of these motifs in
fibroblasts, but it is evident that the activation effects of the
motifs are manifest specifically in B cells but not fibroblasts.
A lymphoid-specific protein binds to the ,uB DNA motif. To
correlate the functional data described above with binding of
a potential lymphoid-specific protein to the p.B motif, we
performed DNase I footprinting experiments using the p.460
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FIG. 4. Effects of mutation in the ,uB motif within the ,u300 IgH
enhancer on transcription in fibroblasts. The p300 IgH enhancers
were tested in NIH 3T3 fibroblasts. Absolute percent conversions of
chloramphenicol to acetylated forms were as follows: p300 WT,
1.1% and ENH-, 0.85%. Other details are as given in the legend to
Fig. 3.
fragment of the IgH enhancer. We compared nuclear ex-
tracts derived from lymphoid cells with extracts from non-
lymphoid cells (Fig. 5 and 6). Proteins bound to E2 and E3
were detected in extracts of both lymphoid (S194 and BJAB)
and nonlymphoid (U-C12:6, 32D, NIH 3T3, EJ, and HeLa)
cells (Fig. S and 6A). A strong footprint over the ,uB DNA
motif was seen in extracts from the two lymphoid cell lines
S194 (murine myeloma) and BJAB (human B-cell lym-
phoma) (Fig. 5, lanes 5 and 6; Fig. 6A, lane 3). No footprint
over the p.B site was observed with nuclear extracts from
U-C12:6, a human glioma (Fig. 5, lane 1), NIH 3T3 mouse
fibroblasts (Fig. 5, lane 3), EJ human bladder carcinoma cells
(Fig. 5, lane 4), and HeLa human cervical carcinoma cells
(Fig. 6A, lane 2). The nuclear extract from the 32D myeloid
precursor cell line protected a larger region around the ,uB
site and had a unique enhanced band in the upper part of the
,uB site (Fig. 5, lane 2). Thus, the 32D nuclear factor(s) has
properties very different from those of the B-cell factor. Our
results confirm that a lymphoid-specific factor or factors in
both murine and human cells bind to the p.B motif.
Interestingly, we also detected a strong lymphoid-specific
footprint between the E2- and E3-binding sites (Fig. 5) which
has not been previously observed. This suggests the possi-
bility of additional lymphoid-specific enhancer elements in
the IgH enhancer (T. Libermann and D. Baltimore, unpub-
lished results).
To confirm that mutation in ,uB decreased binding of the
lymphoid-specific factor, we carried out DNase I footprint-
ing experiments comparing the wild-type ,u460 WT with the
mutant ,u460 ,uB- enhancer. Heparin-agarose fractions of
nuclear extracts derived from HeLa and BJAB cells were
used for this experiment. Again, only the BJAB B-cell line,
not the HeLa carcinoma cell line, extract gave rise to a
footprint over the ,uB site in the wild-type enhancer (Fig.
6A). The mutant ,uB site gave a different DNase digestion
pattern, but it was clear that no protection was detected over
the altered p.B site with an extract from BJAB cells (Fig.
6B). A weak footprint that included the mutant p.B site was
created by the HeLa extract, but this has not been further
studied (Fig. 6B). These results have been confirmed by gel
mobility shift assays (Libermann and Baltimore, unpub-
lished results). Only a wild-type, not a mutant ,uB, oligonu-
cleotide forms a specific complex in B cells but not in glioma,
epithelial, and fibroblast cells, and only the wild-type oligo-
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FIG. 5. Detection of IgH enhancer-binding factors by a DNase I
footprinting assay using wild-type p.460 IgH enhancer fragment
labeled at the 5' end of the noncoding strand. Labeled p.460
enhancer fragment was incubated with 20 p.g of total nuclear extract
from U-Cl2:6 glioma cells (lane 1), 32D myeloid precursor cells (lane
2), NIH 3T3 fibroblasts (lane 3), EJ bladder carcinoma cells (lane 4),
BJAB B-lymphoid cells (lane 5), and S194 myeloma cells (lane 6).
Lane 7 was a control reaction without protein. A G+A Maxam-
Gilbert sequence reaction of the same IgH enhancer fragment was
run in lane 8. The positions and names of the IgH enhancer elements
are indicated by the boxes to the right of gel, together with
coordinates of each site according to Ephrussi et al. (8).
nucleotide specifically competes with this particular com-
plex (Libermann and Baltimore, unpublished results). Thus,
mutation in the ,uB site indeed decreases affinity for a
lymphoid-specific p.B-binding factor.
DISCUSSION
We have found that the [LB site found just downstream of
the E3 site in the IgH enhancer is a crucial component of the
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FIG. 6. Binding of nuclear factors to wild-type and mutant ,uB
sites in the IgH enhancer in a DNase I footprinting assay using
wild-type ,u460 WT (A) and mutant ,u460 ,uB- (B) IgH enhancer
fragments labeled and cut as for Fig. 5. Labeled enhancer fragments
were incubated with 3 jig of heparin-agarose-purified nuclear extract
from HeLa (lane 2) or BJAB (lane 3) cells. Lane 1 was a control
reaction without protein. A G+A sequence reaction of the same
DNA fragments was run as a marker (lane 4). The positions and
names of enhancer elements in the IgH enhancer are indicated by
solid boxes together with coordinates (8, 16) of each site. The box
with dashed lines in panel B indicates the position of the altered ,uB
site.
IgH gene regulatory region. The ,uB motif binds a lymphoid-
specific nuclear factor, and its alteration substantially re-
duces IgH enhancer activity in lymphoid cells. In addition,
combined mutation of both ,uB and OCTA sites drastically
impairs transcriptional activity of the IgH enhancer. Similar
results have been obtained independently by Nelsen et al.
(24). It appears that the ability of the IgH enhancer to induce
transcription in lymphoid cells but not in nonlymphoid cells
is for the most part a consequence of the combined action of
two enhancer elements, ,uB and OCTA. In contrast to OCTA
(45), however, the ,uB element by itself does not express
enhancer activity but needs interaction with another element
to function. Our results indicate that the p.B site, together
with the OCTA site and probably others, determines the
tissue-restricted expression of the IgH gene.
Our purpose in undertaking these studies was to define
more completely which enhancer elements contribute to the
lymphoid-restricted expression of the IgH gene. The ,uB
motif manifests features of a second lymphoid-specific ele-
ment in the IgH enhancer. Nevertheless, combined mutation
of both the ,uB and OCTA sites leaves considerable residual
enhancer activity that can only be explained by the action of
further enhancer elements, possibly the E boxes (6, 8, 16, 34,
43). Indeed, preliminary evidence suggests that an mRNA
coding for an E-box-binding protein is preferentially ex-
pressed in B cells (C. Murre and D. Baltimore, unpublished
results).
B-cell specificity of the IgH gene is apparently regulated
by both positive-acting B-cell-specific enhancer elements
and negative-acting non-B-lymphoid-specific elements. In-
deed, recent evidence suggests that repression of the IgH
enhancer plays a role in silencing of the enhancer in non-B
cells (30, 44). Two negative elements that flank the 700-bp
IgH enhancer have been identified and might be related to
matrix attachment points (30). It is therefore not surprising
that a 300-bp fragment of the IgH enhancer (jx300) is some-
what transcriptionally active in nonlymphoid cells, whereas
the whole ,u00 IgH enhancer is inactive in nonlymphoid
cells (16). An apparent negative element has been located to
a region between the tLE1 and ,uE2 enhancer elements (44).
This negative element suppresses enhancer activity in non-B
cells and is absent in the p.300 fragment (44). However, even
the 300-bp fragment which lacks identified negative elements
appears to be a very weak enhancer in NIH 3T3 cells if
compared with B cells. Mutation of either the OCTA or ,uB
site leads to increased activity of ,u300 in NIH 3T3 cells,
suggesting that factors binding to these sites in NIH 3T3 cells
might repress rather than enhance activity. Another less
likely explanation might be that mutation of these sites
allows binding of positive factors to the mutated sites that
are specific for NIH 3T3 cells. Negative regulation may
contribute to lymphoid specificity of the IgH enhancer.
However, positive-acting lymphoid-specific elements are
essential to explain all aspects of lymphoid-specific IgH
enhancer expression.
Mutation in the OCTA site within ,u300 did not lead to as
drastic a decrease in transcriptional activity as previously
reported (16) but reduced CAT activity by only 50 to 60% in
different B-cell lines. This discrepancy might be due to the
use of different cell lines in the previous report. More
important, mutation of the [LB site in all cell lines revealed a
greater decrease in transcription than did mutation in the
OCTA site. This difference was independent of the length of
IgH enhancer fragment tested. This difference was particu-
larly striking in the pre-B-cell line PD31 and might be due to
different amounts of NF-,uB and Oct-2 protein in PD31 pre-B
cells and S194 myeloma cells. PD31 cells might contain
relatively more NF-,uB than S194 cells. Interestingly, in the
B orientation p.300 expressed much higher transcriptional
activity than did ,u700, whereas in the A orientation ,u700
was more active than ,u300. This effect might be due to the
difference in activity of the various enhancer elements
dependent on the distance to the c-fos promoter. In the B
orientation but not in the A orientation, E3, ,uB, and OCTA
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are closer to the transcription initiation point in p.300 than in
ix700.
Using the DNase I footprinting technique, we have dem-
onstrated specific binding of a nuclear factor or factors,
termed NF-,uB, to the ,uB site of the murine IgH enhancer.
NF-,uB seems to be present only in B-lymphoid and some
T-lymphoid (unpublished results) cells as well as in macro-
phage cell lines (unpublished results) of both human and
mouse origin but is absent in fibroblasts, epithelial cells, and
glial cells. Partial protection of the ,uB site was also detected
in nuclear extracts from the myeloid precursor cell line 32D,
even though the footprint pattern over the ,uB site was
strikingly different from that created by nuclear extracts
from lymphoid cells. This finding suggests the presence of a
factor related but not identical to NF-,uB. Both DNase I
footprinting analysis and gel mobility shift experiments
(unpublished results) have confirmed that the mutant jiB site
is unable to bind NF-,uB.
Unexpectedly, we observed an additional putative lym-
phoid-specific footprint in the region between the ubiqui-
tously protected E2 and E3 sites, raising the possibility that
a third lymphoid-specific enhancer element is present in the
IgH enhancer. We have preliminary evidence that this new
site is indeed a functional enhancer (Libermann and Balti-
more, unpublished results).
Lymphoid-specific protection over the ,iB site has been
previously suggested by the experiments of Ephrussi et al.
(8) with in vivo experiments and by Augereau and Chambon
(2) with in vitro DNase footprinting. Araki et al. (1) have
recently reported the purification of a nuclear protein from a
murine myeloma that binds to a site of the human IgH
enhancer that is homologous to the murine IgH enhancer ,uB
site, although the murine jiB sequence differs in 4 of 16
nucleotides from the human jiB-like site. We now demon-
strate that the murine ,uB site has features resembling the
human homolog (see also Nelsen et al. [24]). Thus, like the
OCTA motif, the jiB motif and its factor are important
elements of the IgH enhancer that are apparently conserved
between species.
Araki et al. (1) showed that their factor is capable of
inducing transcription of the human IgH gene when intro-
duced into mouse L cells containing a transfected rearranged
IgH gene. Nuclear extracts from nonlymphoid cell lines
were unable to induce high expression of the IgH gene in L
cells. Our mutational analysis of the jiB motif in the murine
IgH enhancer provides evidence that the murine jiB site has
features similar to the human homolog. Our results show
directly that the jiB motif plays a crucial role in IgH
enhancer activity and together with the DNase footprinting
experiments support the notion that the jiB motif acts as a
lymphoid-specific enhancer component. Indeed, the jiB mo-
tif appears to have a stronger effect on IgH enhancer
transcription in pre-B cells than does the OCTA element.
There is an important difference between the function of
the OCTA and the jiB elements. The OCTA motif acts as a
lymphoid-specific enhancer independently of other enhancer
elements (45), whereas even a tetramer of the jiB motif is
completely devoid of enhancer activity in a variety of cell
lines tested. Nevertheless, transcription of a small 70-bp
fragment of the IgH enhancer that contains the E3 and ,uB
sites works as an enhancer element and is dependent on the
integrity of the jiB site. There are several explanations for
the lack of independent enhancer activity of the jiB element.
(i) We might have missed part of the NF-jiB-binding site
when constructing the oligonucleotide. This is unlikely,
because our oligonucleotide contains flanking regions on
both ends extending well over the putative binding site
described by Araki et al. (1) for the human jiB-like element
and functionally defined by Nelsen et al. (24). (ii) The jiB
motif is inactive in the context of the c-fos promoter/CAT
construct. This is also unlikely, because the jiB element acts
as an enhancer in this plasmid in the context of other IgH
enhancer elements. (iii) The spacing of the jiB motifs in the
multimers does not allow "productive" NF-jiB binding to
the element. At present we have no evidence against or for
this possibility. (iv) Interactions between NF-,uB and pro-
teins binding to additional enhancer elements are needed for
the function of the jiB element, or NF-,iB binds only after
modulation of the jiB site by an additional enhancer element.
Our results support this explanation, because alteration of
either the jiB or the E3 site within the ,u70 IgH enhancer
fragment abolished most if not all enhancer activity of this
fragment. Whether E3 is the only enhancer element that
directly interacts with jiB we do not yet know. Also, it is not
clear whether NF-,uB and NF-p.E3 can directly interact.
Interestingly, Meyer and Neuberger (22) have recently
identified an enhancer 3' of the immunoglobulin K gene that
contains a jiB-like sequence flanked by an E3-like motif,
albeit in orientation inverse to that of the IgH enhancer. The
novel immunoglobulin K enhancer they describe also con-
tains a sequence similar to that of the new enhancer element
found between E2 and E3 in the IgH enhancer (Libermann
and Baltimore, unpublished results). Interactions between
different enhancer elements are likely to be important, as
shown by the lack of demonstrable activity of jiB oligonu-
cleotides. The mechanism by which other enhancer elements
and their associated binding proteins modulate the transcrip-
tional effect of the jiB motif will be an interesting area for
future research.
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